专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140205656A1 MODIFIED CATIONIC LIPOSOME ADJUVANTS 审中-公开
标题翻译：改性阳离子脂质体
公开(公告)号：US20140205656A1
公开(公告)日：2014-07-24
申请号：US14162511
申请日：2014-01-23
申请人： Statens Serum Institut
发明人： Dennis Christensen , Karen Smith Korsholm , Else Marie Agger , Peter Andersen
IPC分类号： A61K9/127 , A61K39/12 , A61K39/015 , A61K39/145 , A61K39/04
CPC分类号： A61K9/127 , A61K9/1272 , A61K39/015 , A61K39/04 , A61K39/118 , A61K39/12 , A61K39/145 , A61K2039/55555 , Y02A50/412
摘要： The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CDS response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer.
摘要翻译：本发明涉及疫苗与包含阳离子脂质体的佐剂的疫苗，其中中性脂质已经引入脂质体中以改变凝胶 - 液相转变，从而改变IgG亚型应答并增强脂质体佐剂的CD8应答。该技术可用于增加IgG2抗体的产生。已经显示这种亚型抗体（对应于人类中的IgG3的小鼠中的IgG2）选择性地与先天免疫细胞表面上的Fc激活受体结合，导致增强的促炎反应，从而更高效的免疫应答，并具有较高的保护水平动物模型例如疟疾和衣原体。选择性地引起更高水平的IgG2抗体的佐剂的使用将改善疫苗的效果，例如，针对细胞内感染。此外，该技术可用于诱导CD8应答，其已被报道以改善疫苗对例如抗体的作用。已显示HPV，HIV，流感和癌症选择性地与先天免疫细胞表面上的Fc激活受体结合，导致增强的促炎反应，从而在例如动物模型中具有较高保护水平的更有效的免疫应答。疟疾和衣原体。选择性地引起更高水平的IgG2抗体的佐剂的使用将改善疫苗的效果，例如，针对细胞内感染。此外，该技术可以用于诱导CDS反应，其已经被报道以改善疫苗对抗体的作用。 HPV，HIV，流感和癌症。

IPRDB

热门服务

关于我们

友情链接

联系方式